Disease: Adult Solid Neoplasm ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0280099
Disease: Adult Solid Neoplasm
Adult Solid Neoplasm 		0.020 Biomarker group BEFREE The FDA has approved entrectinib for patients with any solid tumor bearing <i>NTRK</i> fusions, making it the second TRK inhibitor to receive a tissue-agnostic approval; larotrectinib was the first. 31471291 2019
CUI: C0280099
Disease: Adult Solid Neoplasm
Adult Solid Neoplasm 		0.020 Biomarker group BEFREE To our knowledge, this is the first clinical evidence of efficacy for therapeutic inhibition of TRKA in a solid tumor, illuminating a genomic-driven strategy to identify CRCs reliant on this oncogene to be clinically targeted with entrectinib. 26563355 2016